Hormonal hair loss
Also known as: female pattern hair loss, androgenic alopecia
Medically reviewed by Hormone Journal Editorial Team · Last reviewed 2026-05-22
Hormonal hair loss (androgenic alopecia) affects up to 50% of women by age 50, causing diffuse crown thinning driven by androgen sensitivity and genetic predisposition.
What it is
Hormonal hair loss — clinically called androgenic alopecia (AGA) or female pattern hair loss (FPHL) — affects an estimated 50% of women at some point in their lives, with prevalence rising sharply after menopause. Androgenic alopecia is a genetically predetermined, progressive condition in which scalp hair follicles miniaturize in response to androgen signalling, producing finer, shorter hairs over time until the follicle becomes dormant. In women, the pattern differs from male-pattern baldness: the frontal hairline is typically preserved while hair thins diffusely across the crown and widens along the centre part — a presentation graded using the Ludwig scale (I–III). In Canada, FPHL is one of the most common reasons women seek dermatology or endocrinology referrals, yet it remains underdiagnosed in primary care.
Causes and mechanism
Despite the name androgenic alopecia, the exact hormonal mechanism is still being worked out. The leading model holds that dihydrotestosterone (DHT) — a potent androgen converted from testosterone by the enzyme 5-alpha reductase — binds to androgen receptors in genetically susceptible follicles and shortens the anagen (growth) phase while prolonging the telogen (resting) phase. Over repeated cycles, follicles shrink and terminal hairs are replaced by fine vellus hairs.
Importantly, many women with FPHL have normal circulating androgen levels; local follicular sensitivity, not systemic androgen excess, appears to drive the process in a significant proportion of cases. Hormonal transitions that commonly trigger or accelerate hair loss include:
| Trigger | Mechanism |
|---|---|
| Menopause | Falling estrogen reduces follicle-protective effects; relative androgen excess increases |
| Postpartum (telogen effluvium) | Estrogen drop after delivery shifts follicles into telogen en masse |
| Polycystic ovary syndrome (PCOS) | Elevated androgens (testosterone, DHEA-S) accelerate miniaturization |
| Thyroid dysfunction | Both hypo- and hyperthyroidism disrupt the hair cycle independently of androgens |
| Oral contraceptive changes | Progestins with high androgenic activity can worsen FPHL in susceptible individuals |
Genetics play a substantial role: variants in the androgen receptor gene (AR) on the X chromosome are the best-replicated susceptibility loci, though dozens of additional loci have been identified in genome-wide association studies.
Symptoms and diagnosis
The hallmark symptom is gradual diffuse thinning at the crown and a widening centre part, without a receding frontal hairline. Patients often notice increased shedding on brushing or washing, reduced ponytail thickness, or scalp visibility under bright light. Unlike scarring alopecias, the scalp surface remains smooth and follicular openings are preserved on dermoscopy.
Diagnosis is primarily clinical. Canadian dermatologists typically combine:
- History — onset, rate of progression, family history, menstrual irregularity, recent stressors, medications
- Pull test — more than 6 hairs extracted from 60 pulled suggests active shedding
- Dermoscopy — hair shaft diameter variability >20% is a key FPHL marker
- Blood work — TSH, ferritin, CBC, total and free testosterone, DHEA-S, prolactin (available through LifeLabs or Dynacare across most provinces); SHBG and fasting insulin if PCOS is suspected
A scalp biopsy is reserved for diagnostically uncertain cases. The Ludwig classification grades severity: Grade I (mild widening of centre part), Grade II (wider part with reduced volume), Grade III (diffuse thinning with near-complete crown loss).
Treatment options
No treatment reverses FPHL completely, but several slow progression and partially restore density:
Topical minoxidil is the only Health Canada–approved topical treatment for FPHL. The 2% solution is approved for women; the 5% foam is widely used off-label and supported by clinical evidence showing superior regrowth. Minoxidil prolongs anagen and increases follicle size; it must be used indefinitely — stopping leads to loss of regained hair within 3–6 months.
Oral minoxidil at low doses (0.25–1 mg/day) is increasingly prescribed off-label in Canada and has shown efficacy in several randomized trials with a more convenient regimen than topical application.
Anti-androgens are used when androgen excess is confirmed or suspected:
- Spironolactone (100–200 mg/day) blocks androgen receptors and is the most commonly prescribed systemic option for FPHL in Canadian women; requires reliable contraception in premenopausal patients due to teratogenicity risk.
- Finasteride (1–2.5 mg/day) inhibits 5-alpha reductase and is used off-label in postmenopausal women; contraindicated in pregnancy.
- Oral contraceptives with low androgenic progestins (e.g., drospirenone, norgestimate) may help women with concurrent PCOS.
Procedural options include platelet-rich plasma (PRP) injections, low-level laser therapy (LLLT) devices (some Health Canada–cleared), and hair transplantation for stable, advanced cases.
Canadian patients can access prescription options through in-person dermatology or endocrinology referrals, or through virtual care platforms such as Felix, Maple, Cleo, or Phoenix, which offer asynchronous prescribing for minoxidil and spironolactone in most provinces.
When to see a clinician in Canada
See a physician or nurse practitioner promptly if hair loss is rapid (weeks rather than months), patchy, associated with scalp inflammation or scarring, or accompanied by signs of androgen excess (new acne, hirsutism, menstrual irregularity, clitoromegaly). These features suggest a secondary cause — PCOS, adrenal tumour, or a scarring alopecia — that requires investigation beyond FPHL management. Dermatology wait times in Canada can exceed 6–12 months in many provinces; a GP or virtual-care provider can initiate bloodwork and topical minoxidil while a referral is pending.
Limitations and open questions
Research is still emerging on several fronts. The relative contributions of local androgen sensitivity versus systemic hormone levels remain incompletely understood, and no biomarker reliably predicts treatment response. Evidence for oral minoxidil in women comes largely from small trials; large randomized controlled data are limited. The long-term safety of low-dose oral minoxidil in women has not been established in trials exceeding two years. Health Canada has not issued specific guidance on off-label use of finasteride or oral minoxidil for FPHL, leaving prescribers to rely on international guidelines (Endocrine Society, British Association of Dermatologists). The psychological burden of FPHL — including anxiety and reduced quality of life — is well documented but undertreated; Canadian mental health integration into hair-loss care pathways is inconsistent.
FAQs
What is the difference between hormonal hair loss and telogen effluvium?
Hormonal hair loss (androgenic alopecia) is a chronic, progressive condition driven by genetic androgen sensitivity, producing a predictable pattern of crown thinning that persists indefinitely without treatment. Telogen effluvium is a temporary, diffuse shed triggered by a specific stressor — childbirth, illness, crash dieting, or surgery — in which up to 30% of follicles shift into the resting phase simultaneously; most cases resolve within 3–6 months once the trigger is removed. The two conditions can coexist, and a postpartum shed sometimes unmasks underlying FPHL that continues after the telogen effluvium resolves.
Is hormonal hair loss covered by provincial health insurance in Canada?
Diagnosis and medical management — including GP or dermatologist visits, bloodwork through LifeLabs or Dynacare, and prescription medications — are covered under provincial health insurance plans. The medications themselves vary: spironolactone and finasteride are listed on most provincial formularies for their primary indications, but coverage for hair-loss use depends on the province and whether a prescriber codes the indication. Topical minoxidil 2% is available over the counter without a prescription; the 5% foam requires a prescription in some provinces. Procedural treatments such as PRP and hair transplantation are not covered.
Can menopause cause hair loss even if my androgen levels are normal?
Yes. Falling estrogen at menopause reduces the follicle-protective effects of estradiol — estrogen receptors are expressed in hair follicles and appear to prolong the growth phase — so even without a rise in absolute androgen levels, the relative androgen-to-estrogen ratio shifts unfavourably. Studies estimate that up to 40% of postmenopausal women experience some degree of FPHL. Menopausal hormone therapy (MHT) does not reliably reverse established FPHL, but some evidence suggests it may slow progression, particularly with estrogen-dominant regimens.
How long does minoxidil take to work, and what happens if I stop?
Most women using topical 5% minoxidil see stabilization of shedding within 3 months and measurable regrowth by 6–12 months; peak response typically occurs around 12–18 months of consistent use. In clinical trials, approximately 60% of women using 5% minoxidil foam reported improvement versus 40% with the 2% solution. If minoxidil is stopped, the hair gained during treatment is lost within 3–6 months because the drug does not alter the underlying genetic susceptibility — it only sustains follicle activity while present.
Does PCOS-related hair loss respond differently to treatment than ordinary female pattern hair loss?
PCOS-associated FPHL involves confirmed androgen excess, so anti-androgen therapies — particularly spironolactone at 100–200 mg/day — tend to show stronger benefit than in women with normal androgen levels. Treating the underlying PCOS (with lifestyle modification, metformin, or combined oral contraceptives containing low-androgenic progestins) can reduce circulating androgens and slow follicle miniaturization. Minoxidil is still typically added for direct follicle stimulation. Response is gradual; most guidelines recommend reassessing after at least 12 months of combined therapy before concluding treatment has failed.
Sources
- Androgenetic Alopecia — StatPearls, NCBI Bookshelf (Ho, Sood, Zito; updated January 2024)
- Hormonal therapy in female pattern hair loss — PMC / NIH (Vujovic & Del Marmol, 2017)
- The Hormonal Background of Hair Loss in Non-Scarring Alopecias — PMC / NIH (2024)
- Androgenetic alopecia — MedlinePlus Genetics, U.S. National Library of Medicine
- Female Pattern Hair Loss: A Clinical, Pathophysiologic, and Therapeutic Review — Journal of the American Academy of Dermatology
- Minoxidil and its use in hair disorders: a review — Drug Design, Development and Therapy (Badri & Nessel, 2023)